These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 30123958)
1. Millepachine showed novel antitumor effects in cisplatin-resistant human ovarian cancer through inhibiting drug efflux function of ATP-binding cassette transporters. Wu W; Liu Y; Ye H; Li Z Phytother Res; 2018 Dec; 32(12):2428-2435. PubMed ID: 30123958 [TBL] [Abstract][Full Text] [Related]
2. Millepachine, a potential topoisomerase II inhibitor induces apoptosis via activation of NF-κB pathway in ovarian cancer. Wu W; Ma B; Ye H; Wang T; Wang X; Yang J; Wei Y; Zhu J; Chen L Oncotarget; 2016 Aug; 7(32):52281-52293. PubMed ID: 27447570 [TBL] [Abstract][Full Text] [Related]
3. Millepachine, a novel chalcone, induces G2/M arrest by inhibiting CDK1 activity and causing apoptosis via ROS-mitochondrial apoptotic pathway in human hepatocarcinoma cells in vitro and in vivo. Wu W; Ye H; Wan L; Han X; Wang G; Hu J; Tang M; Duan X; Fan Y; He S; Huang L; Pei H; Wang X; Li X; Xie C; Zhang R; Yuan Z; Mao Y; Wei Y; Chen L Carcinogenesis; 2013 Jul; 34(7):1636-43. PubMed ID: 23471882 [TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers. Long Q; Xiel Y; Huang Y; Wu Q; Zhang H; Xiong S; Liu Y; Chen L; Wei Y; Zhao X; Gong C J Biomed Nanotechnol; 2013 Jun; 9(6):965-75. PubMed ID: 23858960 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma. Ge T; Liu T; Guo L; Chen Z; Lou G Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657 [TBL] [Abstract][Full Text] [Related]
6. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling. Chau WK; Ip CK; Mak AS; Lai HC; Wong AS Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058 [TBL] [Abstract][Full Text] [Related]
7. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways. Shen W; Liang B; Yin J; Li X; Cheng J Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462 [TBL] [Abstract][Full Text] [Related]
8. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919 [TBL] [Abstract][Full Text] [Related]
9. Dual-Targeted Zeolitic Imidazolate Frameworks Drug Delivery System Reversing Cisplatin Resistance to Treat Resistant Ovarian Cancer. Xing Y; Jing R; Tang X; Jiang Z Int J Nanomedicine; 2024; 19():6603-6618. PubMed ID: 38979533 [TBL] [Abstract][Full Text] [Related]
10. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer]. Qi C; Zhang QH; Li JX Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111 [TBL] [Abstract][Full Text] [Related]
11. Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV. Yuan Y; Zhang J; Zeng H; Gui A; Yan Y; Zou A; Yang L Biochem Biophys Res Commun; 2024 Nov; 734():150616. PubMed ID: 39232456 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85. Wu D; Lu P; Mi X; Miao J Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155 [TBL] [Abstract][Full Text] [Related]
13. The anthraquinone derivative KA-4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin. Zhao Y; Li X; Xu S; Yang Y; Chen Q; Li J; Tian W; Zhang Q; Hou H; Li D Mol Carcinog; 2024 Nov; 63(11):2090-2102. PubMed ID: 39092774 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells. Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458 [TBL] [Abstract][Full Text] [Related]
15. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling. Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764 [TBL] [Abstract][Full Text] [Related]
16. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion. Wang H; Luo Y; Qiao T; Wu Z; Huang Z J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003 [TBL] [Abstract][Full Text] [Related]
17. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer. Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776 [TBL] [Abstract][Full Text] [Related]
18. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Yang YI; Kim JH; Lee KT; Choi JH Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308 [TBL] [Abstract][Full Text] [Related]
19. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711 [TBL] [Abstract][Full Text] [Related]